This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Turnidge, J.
Right arrow Articles by Paterson, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Turnidge, J.
Right arrow Articles by Paterson, D. L.

Next Article 

Clinical Microbiology Reviews, July 2007, p. 391-408, Vol. 20, No. 3
0893-8512/07/$08.00+0     doi:10.1128/CMR.00047-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Setting and Revising Antibacterial Susceptibility Breakpoints

John Turnidge1* and David L. Paterson2,3,4

Division of Laboratory Medicine, Women's and Children's Hospital, North Adelaide, Australia,1 Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania,2 University of Queensland, Brisbane, Australia,3 Queensland Health Pathology Services, Royal Brisbane and Women's Hospital, Brisbane, Australia4

Clinical microbiology laboratories need to communicate results of antibacterial susceptibility testing to prescribers. Sophisticated prescribers who are knowledgeable of the pharmacokinetics and pharmacodynamics of antibacterials may desire no more information than the MIC of the drug in question. However, most prescribers require interpretation of antibacterial susceptibility testing results. Breakpoints can assist in determining if an antibacterial is potentially useful in the treatment of a bacterial infection. Breakpoints should be set prior to an antibacterial being used clinically. Breakpoint setting requires integration of knowledge of the wild-type distribution of MICs, assessment of the pharmacokinetics/pharmacodynamics of the antibacterial, and study of the clinical outcome of infections when the antibacterial is used. It is mandatory that breakpoints be reviewed when antibacterial agents have been in clinical use for some time, particularly if mechanisms of bacterial resistance to the drug have been described. In general, greater amounts of information on the pharmacokinetics and pharmacodynamics of an antibacterial are available when breakpoints need to be revised. However, the opportunity to conduct randomized clinical studies of an antibacterial declines after the drug has been released commercially. Well-designed observational clinical studies are therefore necessary in order to provide reliable data to inform those reevaluating breakpoints. Breakpoint-setting organizations may also play a role in developing phenotypic tests for detection of resistance mechanisms, as this information may complement use of the breakpoint in some circumstances.

* Corresponding author. Mailing address: Division of Laboratory Medicine, Women's and Children's Hospital, 72 King William Rd., North Adelaide, South Australia, Australia. Phone: 1 8 81616873. Fax: 61 8 81616189. E-mail: john.turnidge{at}cywhs.sa.gov.au

Clinical Microbiology Reviews, July 2007, p. 391-408, Vol. 20, No. 3
0893-8512/07/$08.00+0     doi:10.1128/CMR.00047-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Pfaller, M. A., Diekema, D. J., Ghannoum, M. A., Rex, J. H., Alexander, B. D., Andes, D., Brown, S. D., Chaturvedi, V., Espinel-Ingroff, A., Fowler, C. L., Johnson, E. M., Knapp, C. C., Motyl, M. R., Ostrosky-Zeichner, L., Sheehan, D. J., Walsh, T. J., for the Clinical and Laboratory Standards Institut, (2009). Wild-Type MIC Distribution and Epidemiological Cutoff Values for Aspergillus fumigatus and Three Triazoles as Determined by the Clinical and Laboratory Standards Institute Broth Microdilution Methods. J. Clin. Microbiol. 47: 3142-3146 [Abstract] [Full Text]  
  • Bell, J. M., Turnidge, J. D., Jones, R. N. (2009). Development of a Disk Diffusion Method for Testing Moraxella catarrhalis Susceptibility Using Clinical and Laboratory Standards Institute Methods: a SENTRY Antimicrobial Surveillance Program Report. J. Clin. Microbiol. 47: 2187-2193 [Abstract] [Full Text]  
  • Cirillo, I., Vaccaro, N., Turner, K., Solanki, B., Natarajan, J., Redman, R. (2009). Pharmacokinetics, Safety, and Tolerability of Doripenem After 0.5-, 1-, and 4-Hour Infusions in Healthy Volunteers. J Clin Pharmacol 49: 798-806 [Abstract] [Full Text]  
  • Chin, B. S., Seo, W. Y., Paterson, D. L., Potoski, B. A., Peleg, A. Y. (2009). Cefepime MIC Breakpoint Resettlement in Gram-Negative Bacteria. Antimicrob. Agents Chemother. 53: 337-338 [Full Text]  
  • Traczewski, M. M., Brown, S. D. (2008). Proposed MIC and Disk Diffusion Microbiological Cutoffs and Spectrum of Activity of Retapamulin, a Novel Topical Antimicrobial Agent. Antimicrob. Agents Chemother. 52: 3863-3867 [Abstract] [Full Text]  
  • Nemati, M., Hermans, K., Lipinska, U., Denis, O., Deplano, A., Struelens, M., Devriese, L. A., Pasmans, F., Haesebrouck, F. (2008). Antimicrobial Resistance of Old and Recent Staphylococcus aureus Isolates from Poultry: First Detection of Livestock-Associated Methicillin-Resistant Strain ST398. Antimicrob. Agents Chemother. 52: 3817-3819 [Abstract] [Full Text]  
  • Marquez, C., Labbate, M., Raymondo, C., Fernandez, J., Gestal, A. M., Holley, M., Borthagaray, G., Stokes, H. W. (2008). Urinary Tract Infections in a South American Population: Dynamic Spread of Class 1 Integrons and Multidrug Resistance by Homologous and Site-Specific Recombination. J. Clin. Microbiol. 46: 3417-3425 [Abstract] [Full Text]  
  • Peleg, A. Y., Seifert, H., Paterson, D. L. (2008). Acinetobacter baumannii: Emergence of a Successful Pathogen. Clin. Microbiol. Rev. 21: 538-582 [Abstract] [Full Text]  
  • Garcia-Cobos, S., Campos, J., Roman, F., Carrera, C., Perez-Vazquez, M., Aracil, B., Oteo, J. (2008). Low {beta}-Lactamase-Negative Ampicillin-Resistant Haemophilus influenzae Strains Are Best Detected by Testing Amoxicillin Susceptibility by the Broth Microdilution Method. Antimicrob. Agents Chemother. 52: 2407-2414 [Abstract] [Full Text]  
  • Simjee, S., Silley, P., Werling, H. O., Bywater, R. (2008). Potential confusion regarding the term 'resistance' in epidemiological surveys. J Antimicrob Chemother 61: 228-229 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»